Zimmer Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Zimmer Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-37,500	Closed	-$209K	–	136
2026 Q1	$209K	Buy	+37,500	New	+$286K	0.01%	123

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Zimmer Partners's KPTI Position: Q2 2026 in Review

Zimmer Partners sold out of Karyopharm Therapeutics (KPTI) in Q2 2026, closing a stake of 37,500 shares — an estimated $209K sold.

Zimmer Partners first reported a position in KPTI in Q1 2026 and held it in 1 quarter. The position peaked at $209K in Q1 2026. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Zimmer Partners reported no remaining Karyopharm Therapeutics position as of Q2 2026 after selling out during the quarter.
Zimmer Partners sold 37,500 Karyopharm Therapeutics shares in Q2 2026, an estimated $209K.
Zimmer Partners first reported a position in Karyopharm Therapeutics in Q1 2026 and held it in 1 quarter.
Zimmer Partners's Karyopharm Therapeutics position peaked at $209K in Q1 2026.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Zimmer Partners's 13F filing for Q2 2026, filed 14 Aug 2026.